Vir Biotec applying multiple platforms to address public health risk from coronavirus
On Jan. 22, 2020, Vir Biotech announced it was working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV.
Tags:
Source: Vir Biotechnology
Credit:
